WO2004009709A1 - 非天然型標識化アミノ酸および該アミノ酸-tRNA結合体の作製方法 - Google Patents
非天然型標識化アミノ酸および該アミノ酸-tRNA結合体の作製方法 Download PDFInfo
- Publication number
- WO2004009709A1 WO2004009709A1 PCT/JP2003/008970 JP0308970W WO2004009709A1 WO 2004009709 A1 WO2004009709 A1 WO 2004009709A1 JP 0308970 W JP0308970 W JP 0308970W WO 2004009709 A1 WO2004009709 A1 WO 2004009709A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- labeled
- protein
- compound
- labeled amino
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 159
- 238000000034 method Methods 0.000 title claims abstract description 64
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 100
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 100
- 150000001875 compounds Chemical class 0.000 claims abstract description 93
- 238000002372 labelling Methods 0.000 claims abstract description 44
- 230000014616 translation Effects 0.000 claims abstract description 44
- 238000001243 protein synthesis Methods 0.000 claims abstract description 33
- 125000003118 aryl group Chemical group 0.000 claims abstract description 27
- 239000000126 substance Substances 0.000 claims description 61
- 108020004566 Transfer RNA Proteins 0.000 claims description 40
- 108020004705 Codon Proteins 0.000 claims description 35
- 230000027455 binding Effects 0.000 claims description 35
- 108010090804 Streptavidin Proteins 0.000 claims description 27
- 125000006850 spacer group Chemical group 0.000 claims description 27
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 claims description 13
- 230000001130 anti-lysozyme effect Effects 0.000 claims description 11
- 230000002194 synthesizing effect Effects 0.000 claims description 11
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 10
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 10
- 239000005090 green fluorescent protein Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 229940088598 enzyme Drugs 0.000 claims description 9
- 241000282836 Camelus dromedarius Species 0.000 claims description 7
- 238000002875 fluorescence polarization Methods 0.000 claims description 7
- 108020005098 Anticodon Proteins 0.000 claims description 6
- 230000005284 excitation Effects 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 102000016943 Muramidase Human genes 0.000 claims description 5
- 108010014251 Muramidase Proteins 0.000 claims description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 5
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 5
- 239000004325 lysozyme Substances 0.000 claims description 5
- 229960000274 lysozyme Drugs 0.000 claims description 5
- 235000010335 lysozyme Nutrition 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- UUBWXCHLJHRYJT-LNAOLWRRSA-N [(2r,3s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(phosphonooxymethyl)oxolan-3-yl] [(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate Chemical group O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 UUBWXCHLJHRYJT-LNAOLWRRSA-N 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 239000005515 coenzyme Substances 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- QITPDXFBSKZUGJ-UHFFFAOYSA-N 3-(3,5-dihydrodipyrrolo[1,2-d:1',2'-h]pyrimidin-3-yl)propanoic acid Chemical compound C1N2C(CCC(=O)O)C=CC2=CC2=CC=CN21 QITPDXFBSKZUGJ-UHFFFAOYSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 18
- 235000001014 amino acid Nutrition 0.000 description 124
- 235000018102 proteins Nutrition 0.000 description 87
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 125000003277 amino group Chemical group 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- -1 Polypropylene Polymers 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000004007 reversed phase HPLC Methods 0.000 description 10
- 238000013519 translation Methods 0.000 description 10
- 238000001262 western blot Methods 0.000 description 9
- 229960002685 biotin Drugs 0.000 description 8
- 235000020958 biotin Nutrition 0.000 description 8
- 239000011616 biotin Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000001917 fluorescence detection Methods 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 235000018977 lysine Nutrition 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003068 molecular probe Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 2
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 101710086015 RNA ligase Proteins 0.000 description 2
- 101100434317 Rattus norvegicus Ada gene Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- KJBQBMRKSLAQHG-NSHDSACASA-N (2s)-2-(pyren-1-ylamino)propanoic acid Chemical compound C1=C2C(N[C@@H](C)C(O)=O)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 KJBQBMRKSLAQHG-NSHDSACASA-N 0.000 description 1
- KHZVLGLEHBZEPO-QMMMGPOBSA-N (2s)-2-hydrazinyl-3-phenylpropanoic acid Chemical class NN[C@H](C(O)=O)CC1=CC=CC=C1 KHZVLGLEHBZEPO-QMMMGPOBSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UAHFISATLZCITH-NRFANRHFSA-N 3-o-tert-butyl 1-o-(cyanomethyl) (2s)-2-[amino-[(2-methylpropan-2-yl)oxycarbonyl]amino]-2-benzylpropanedioate Chemical compound CC(C)(C)OC(=O)N(N)[C@](C(=O)OC(C)(C)C)(C(=O)OCC#N)CC1=CC=CC=C1 UAHFISATLZCITH-NRFANRHFSA-N 0.000 description 1
- IHDBZCJYSHDCKF-UHFFFAOYSA-N 4,6-dichlorotriazine Chemical compound ClC1=CC(Cl)=NN=N1 IHDBZCJYSHDCKF-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- XEUCQOBUZPQUMQ-UHFFFAOYSA-N Glycolone Chemical compound COC1=C(CC=C(C)C)C(=O)NC2=C1C=CC=C2OC XEUCQOBUZPQUMQ-UHFFFAOYSA-N 0.000 description 1
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 101000584831 Pseudoalteromonas phage PM2 Protein P6 Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108091005971 Wild-type GFP Proteins 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- NZBSAAMEZYOGBA-UHFFFAOYSA-N luminogren Chemical compound C12=NC3=CC=CC=C3N2C(=O)C2=CC=CC3=CC=CC1=C23 NZBSAAMEZYOGBA-UHFFFAOYSA-N 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 1
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B57/00—Other synthetic dyes of known constitution
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B57/00—Other synthetic dyes of known constitution
- C09B57/10—Metal complexes of organic compounds not being dyes in uncomplexed form
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Definitions
- the present invention provides a labeled amino acid in which a labeled compound is bound to an amino acid having an amino acid skeleton containing an aromatic ring such as a benzene ring in a side chain as a non-natural amino acid with or without a spacer. I do.
- a functional protein having a function derived from the labeled compound can be provided with good reproducibility.
- the present invention relates to a novel method for producing an aminoacyl-tRNA capable of supporting a labeled amino acid on a tRNA with high yield.
- Hirao et al. Have developed a protein synthesis system using artificial base pairs (artificial base codon method) (Hirao, I., et al., Nature Biotech., 20, 177-182, 2002).
- the dinucleotide in which the 3′-terminal dinucleotide of the tRNA is deleted and the unnatural amino acid is bound instead is replaced with an RNA ligase.
- the unnatural amino acid can be bound to tRNA by using the chemical aminoacylation method of binding to the tRNA.
- two or more unnatural amino acids can be simultaneously introduced into a protein.
- introducing unnatural amino acids into proteins in this way has made it possible not only to analyze the structure and function of the protein, but also to produce an artificial protein with some function added artificially. Therefore, by using various unlabeled amino acids in which various labeled substances are bound to an amino acid skeleton, a labeled protein incorporating the labeled substances can be obtained.
- the labeled protein is directly used by a method corresponding to each labeled substance, or an enzymatic chemical method or the like when the labeled substance is an enzyme substrate or an antigenic substance. Can be detected and / or purified by indirect methods such as enzyme immunochemical techniques, and used for various applications in various medical, pharmaceutical, polymer chemistry, biochemistry, etc. There is expected.
- the natural protein synthesis system is tolerant of incorporating any of the 20 natural amino acids into the polypeptide chain without distinction, and is considered to have some tolerance for unnatural amino acids.
- -Introduction of amino acids having a side chain having a bulky molecular structure, such as pyrenylalanine and ferrocenylalanine, into proteins is impossible with a natural protein synthesis system.
- the ribosome has two tRNA uptake sites, one of which is a polypeptide-bound tRNA force and the other is a tRNA carrying unreacted amino acids.
- tRNAs with bulky amino acids cannot be incorporated into ribosomes and cannot be introduced into proteins.
- a fluorescent substance is a substance very highly useful as a labeled substance of a protein.
- luminescent substances in the visible light region can be detected by widely and widely used detection equipment.
- various high-sensitivity detection devices have already been developed and are widely used.
- cell labels and the like are not affected by interference due to intracellular fluorescence, they are extremely useful as labeling compounds.
- these fluorescent substances have large molecular weights, and when used as a labeling compound for non-natural amino acids, it is difficult to introduce them into proteins by a method using a protein synthesis system.
- compounds having various functions such as enzyme reactivity, antigenicity, protein binding and intermolecular interaction besides fluorescence and luminescence are useful as labeling compounds. Therefore, it is desired to solve the problem that the possibility of introduction into a protein is limited by a method using a protein synthesis system depending on the molecular weight of a labeled compound. Disclosure of the invention
- the present invention provides a labeled amino acid that can be introduced into a protein using a protein synthesis system. Offer. Furthermore, the introduction of the labeled amino acid also provides a functional protein having a function derived from the labeled compound.
- the present invention provides a novel method for obtaining a labeled amino acid-tRNA conjugate in good yield.
- the labeled amino acid can be introduced into a protein via a protein synthesis system.
- the present invention provides the following aspects:
- the labeled amino acid
- Labeling compounds include those selected from the group consisting of dye compounds, fluorescent substances, chemical or bioluminescent substances, enzyme substrates, coenzymes, antigenic substances and protein binding substances.
- the labeled amino acid according to any one of the above 1 to 8,
- fluorescent substance according to 11 above wherein the fluorescent substance is a compound having a chemical structure of 4,4-difluoro-4-bora-3a, 4a-diaza-s-indacene as a basic skeleton, a salt thereof, or a derivative thereof. Labeled amino acids,
- the labeled amino acid is labeled with a compound containing 4,4-difluo-5,7-dimethyl-4-bora-3a, 4a-diaz-s-indacene-3-propionic acid or a salt thereof.
- the above method achieved by a synthetic system;
- the labeled amino acid provided by the present invention can be introduced into a protein via a protein synthesis system to synthesize a labeled protein.
- amino acid refers to any compound having a carboxyl group and an amino group in the same molecule, whether natural or unnatural, "Immobilized amino acid” refers to an amino acid bound to a labeling compound.
- the “amino acid skeleton” in the present specification contains a carboxyl group, an amino group, and a portion connecting these amino acids in an amino acid.
- the term “spacer” refers to a moiety that links an amino acid moiety and a labeled compound in a labeled amino acid molecule. That is, when one or more atoms are present between the amino acid side chain and the labeling compound instead of the amino acid side chain in the labeled amino acid molecule being directly bonded to the labeling compound, It is said that the amino acid moiety and the labeling compound are linked via a spacer.
- the spacer only needs to include at least one or more of (:, 0, N, and S in its main chain.
- the main chain structure of the spacer is such that 2 to 10, preferably 3 to 8, more preferably 5, 6 or 7 are bonded in a linear manner, and one double bond is contained in the linear structure.
- the spacer may have one to several, preferably one to five, more preferably one to three ring structures such as a benzene ring and / or a cyclohexyl ring. It may have a cyclic structure such as a benzene ring or a cyclohexyl ring, or a structure in which the cyclic structure is combined with the above-mentioned linear structure.
- Polypropylene, polyisoptene, polystyrene, polyvinyl, polyvinyl chloride examples include polyolefins such as nyl, polyethers such as polyoxyethylene, polyethylene glycolone, and polyvinyl alcohol, polyamides, polyesters, polyimides, polyurethanes, and polycarbonates.
- polyolefins such as nyl
- polyethers such as polyoxyethylene, polyethylene glycolone, and polyvinyl alcohol
- polyamides, polyesters, polyimides, polyurethanes, and polycarbonates it may be advantageous to bind to an amino acid via a spacer in order to more effectively exert its function in the introduced protein.
- binding via a spacer reduces steric hindrance to the labeling substance in the introduced protein.
- the labeled amino acid of the present invention has an aromatic ring in the side chain of the amino acid portion, and a labeled compound is bonded to the aromatic ring via a spacer or without a spacer.
- a labeled compound is bonded to the aromatic ring via a spacer or without a spacer.
- aromatic ring generally refers to any unsaturated cyclic compound. Therefore, it also includes a 5- or 6-membered heteroaromatic ring, or a polycyclic compound having two or more, preferably 2 to 5, more preferably 2 to 3 ring structures.
- the aromatic ring is preferably a benzene ring.
- phenylalanine, tryptophan, and tyrosine are natural aromatic amino acids containing an aromatic ring in the side chain, and a labeled compound is added to the aromatic ring via a spacer or a spacer. Those bound (without a spacer) can be mentioned as preferred examples of the labeled amino acids of the present invention.
- the bond between the amino acid having an aromatic ring and the labeling compound and the bond between the amino acid having an aromatic ring and the labeling compound via a spacer may be made by using a bond between appropriate functional groups.
- the labeled compound is bound with or without a spacer.
- ком ⁇ онентs such as succinimide ester, isothiocyanate, snorephoninolechloride, NBD-halide and dichlorotriazine are used as probes for amino group labeling, and compounds such as alkyl halide, maleimide and aziridine are used as probe for thiol group labeling.
- a probe for labeling a carboxy group a diazomethane compound, an aliphatic bromide, a carpoimide or the like can be used.
- a succinimide ester may be introduced into a labeled compound with or without a spacer, and an amino group may be introduced into the aromatic ring of an amino acid. Both can be connected by a mid bond.
- Amino acids having an amino group introduced into the aromatic ring include, for example, aminophenylalanine.
- the functional group used at this time can be selected and introduced as appropriate, and the bonding method can be selected as appropriate.
- the amide bond can be selectively reacted with the amino groups on the side chain of aminophenylalanine.
- other amino groups may be protected by Bocation or the like, and then de-Bocated after the reaction. This method can be referred to, for example, the description in “Shinsei Kagaku Experimental Course 1 Protein VI Structure-Function Relationship”.
- a dinucleotide pdCpA
- tRNA tRNA
- tRNA tRNA
- an aromatic ring is directly bonded to an atom forming the amino acid skeleton, it is indirectly bonded via at least one, one, two or three atoms of C, 0, N and S Is also good.
- the position at which the spacer or the labeling compound is bonded to the benzene ring may be at the para or meta position with respect to the amino acid skeleton position. Higher, more preferably, particularly preferably in the para position.
- the labeled compound is bound to the functional group of the aromatic ring with or without a spacer.
- aminophenylalanine paraaminophenylalanine and metaaminophenylalanine are preferred.
- a desired function can be added to the labeled amino acid by selecting a labeled compound having a desired function.
- a protein having a function derived from such a labeled compound is referred to as “functional protein”.
- the labeling compound used in the present invention may be a dye compound, a fluorescent substance, a chemical / bioluminescent substance, an enzyme substrate, a coenzyme, an antigenic substance and a protein binding substance known to those skilled in the art.
- a fluorescent substance for use in a protein synthesis system, those having a molecular weight of 1500 or less, preferably 1000 or less, and more preferably 500 or less are good.
- the fluorescent substance include rhodamine, fluorescein (FITC), Texas red, acridine orange, cyber green, Cy3, Cy5, and BODIPY compounds, and all known fluorescent substances including derivatives thereof. Is mentioned.
- a compound containing 4,4-difluoro_4-bora-3a, 4a-daza-s-indacene as a basic skeleton or a salt thereof or a derivative thereof in its chemical structure.
- the compound or a salt thereof or a derivative thereof is also collectively referred to as a BODIPY compound.
- BODIPY (R) FL, BODIPY (R) TR, BODIPY (R) R6G, BODIPY (R) 558/568, and BODIPY (R) 576/589 which have different fluorescent properties.
- Chemical or bioluminescent substances such as luciferin and luminogen or derivatives thereof can also be used as labeling compounds in the present invention.
- the fluorescent labeling compound those having an excitation wavelength in the visible light range (around 400 to 700 nm) and further having an emission wavelength in the visible light range are preferred, and those having a strong emission intensity in an aqueous solution are particularly preferred.
- BODIPY compounds having an excitation wavelength and an emission wavelength within the visible light range.
- BODIPY FL is excited by light of 488 nm and has strong emission in the visible light range. It has a great advantage in that it can be excited with high sensitivity and can be easily detected with existing general-purpose equipment.
- a coenzyme, a substance having antigenicity, a substance known to bind to a specific protein, or the like is appropriately selected according to the function to be imparted to the target protein, and the selected substance is used as a labeling compound. It can be used for the invention. Further, a substrate for a specific enzyme (for example, a substrate for alkaline phosphatase or] 3 galactosidase) can be detected using a color reaction of the enzyme. In addition, proteins labeled with a substance having antigenicity or a substance known to bind to a specific protein can be used in an indirect detection method using an antibody or a binding protein. And has the advantage that purification is simple.
- a functional protein labeled with biotin using the method of the present invention has a function of binding to avidin or streptavidin via biotin.
- a detection system for a specific substance by utilizing the binding with avidin or streptavidin which is chemically labeled with a fluorescent compound or the like.
- various dyes and substances detectable by various biochemical, biochemical, and immunochemical detection methods can be used as the labeling compound.
- one of the commercially available fluorescent dye B0DIPY compounds 4,4-difluoro-5,7-dimethyl-4-bora-3a, 4a-diaza-s-indacene-3-propione
- the acid (4, 4-Dif luoro-5, 7-Dimethyl_4-Bora-3a, 4a-Diaza-s-Indacene-3-Propionic Acid; BODIPY (registered trademark) -FL) was converted to the side chain of aminophosphorylalanine.
- BODIPY FL-labeled aminophenylalanine derivative BODIPY FL-AF having the structure shown in Formula I above, which is bonded to a ring. It can be introduced into a protein in a protein synthesis system, and the obtained protein has the fluorescence characteristics of BODIPY (ie, shows strong luminescence in visible light), and is easily detectable. is there.
- one of the derivatives of the BODIPY compound 6-((4,4-difluoro-5,7-dimethyl-4-bora-3a, 4a-diaza-s-indacene-3-propionyl).
- BODIPY FL-X-amino-phenylalanine (BODIPY FL-X-AF) represented by the above formula II is obtained.
- BODIPY FL-X-aminophenylalanine BODIPY FL-X-AF
- BODIPY R6G-AF BODIPY 576 / 589-AF
- BODIPY 558 / 568-AF BODIPY 558 / 568-AF
- BODIPY FL-AF BODIPY FL-AF and BODIPY 558 / 568-AF.
- the labeled amino acid of the present invention needs to have a binding portion for binding to tRNA, and such a portion includes, for example, dinucleotide (pdCpA).
- pdCpA dinucleotide
- pdCpA may be previously bound to the amino acid, and the amino acid-pdCpA may be labeled with an appropriate labeling compound.
- a labeled amino acid-pdCpA (BODIPY FL-X-AF-pdCpA) having the structure represented by the following formula is obtained.
- BODIPY FL-X-derived above C0-CH 2 _CH 2 - CH 2 - CH 2 - via a spacer consisting of moieties having C -NH- structure
- Aminofue two Ruara Nin - pdCpA (AF-pdCpA)
- BODIPY FL which is a labeling compound are bound.
- the labeled amino acid can also be introduced into a protein in a protein synthesis system, and the obtained protein has the fluorescence characteristics of BODIPY FL (that is, it shows strong luminescence under visible light). It is easily detectable.
- BODIPY FL-X is a marker that already contains the spacer in the present invention. It is particularly useful for the synthesis of the labeled amino acid of the present invention as an insight compound.
- the above-mentioned BODIPY FL-AF or B0DIPY FL-X-AF is particularly preferable. This is because BODIPY FL retains its fluorescent properties and is efficiently incorporated into proteins by the protein synthesis system. For example, when compared to BODIPY FL-labeled lysines, BODIPY FL-K and BODIPY FL-X-K, their incorporation into proteins is significantly higher. See the examples below.
- a functional protein having the above-mentioned labeled amino acid introduced into a desired protein molecule can be obtained.
- the protein may be any desired, and may be enzymes and proteins having the property of binding to specific molecules such as antibodies and streptavidin.
- the present invention also provides a method for synthesizing the functional protein.
- an aminoaminosyl-tRNA in which a labeled amino acid of the present invention and an anticodon corresponding to a codon designed to specifically encode the labeled amino acid are prepared. It is necessary to.
- the amino group of an amino acid is protected by Bocation or the like, and after binding to a dinucleotide (pdCpA), deprotection treatment such as deBocation is performed.
- an amino acid is bound to tRNA by an aminoacyl-tRNA synthetase and then reacted with a labeling compound, or a labeled amino acid is synthesized and conjugated to pdCpA and then bound to tRNA.
- a labeling compound or a labeled amino acid is synthesized and conjugated to pdCpA and then bound to tRNA.
- tRNA used in the 4-base codon method, the artificial base codon method, and the stop codon method cannot be aminoacylated.
- Another disadvantage is that only natural amino acids can be labeled as amino acids.
- the method of once synthesizing a labeled amino acid, binding it to pdCpA, and then binding it to tRNA requires the use of a labeled compound to perform a number of steps from binding of the labeled compound to obtaining the target product. The yield per volume is very low, which is particularly problematic when labeling with expensive substances such as fluorescent modifiers.
- the acid or base used as a reaction reagent may degrade the labeled substance.
- the labeled amino acid-pdCpA conjugate can be efficiently synthesized because the reaction is finally performed with the labeling compound.
- aminofuranalanine when an amino group is bonded to the aromatic ring of the side chain, it is advantageous in that the amino group of the side chain and the amino group of the side chain can be distinguished and labeled.
- the labeled amino acid-pdCpA conjugate can be completely and easily separated and purified from the unreacted amino acid-pdCpA by liquid chromatography.
- various kinds of labeling agents can be easily synthesized.
- the labeled aminoacyl tRNA produced by such a method can be carried out using a cell-free translation system or a protein synthesis system using living cells.
- a cell-free translation system it is preferable to use a 4-base codon method, an artificial base codon method, or a stop codon method.
- the detailed method of the stop codon method is described in Science, 244, p. 182.1989 and J. Am. Chem. Soc., 111, ⁇ ⁇ 8013, 1989, and for the artificial base codon method, Hirao, I., et al., Nature Biotech., 20, 177-182, 2002, and for the 4-base codon method, Hohsaka T., et al., J. Am. Chem.
- the present invention also includes a functional protein synthesized by the above method. Since such a functional protein has characteristics derived from the labeling compound contained in the molecule, various applications can be considered by utilizing the characteristics.
- a labeled protein having an amino acid labeled with a fluorescent compound using the method of the present invention, binding the protein with a substance capable of binding to the protein, and measuring the fluorescence polarization of the conjugate, Substances that can bind proteins can be detected.
- the protein may be reacted with a chip or a plate to which a substance capable of binding to the protein is bound, and the protein may be reacted by measuring the fluorescence after washing or measuring the evanescent fluorescence without washing. It is possible to detect a substance that can bind to the DNA.
- the protein may be bound to cells and subjected to flow cytometry to separate cells having a receptor for the protein, or to incorporate the protein into cells and to examine the distribution of the protein in the cells. it can.
- the functional protein of the present invention can be applied to various fields, such as detection of a change in fluorescence or binding to another substance or search for a binding site environment by fluorescence correlation spectroscopy.
- BODIPY FL-labeled derivatives of streptavidin and ratada anti-lysozyme antibody are shown as examples of the functional protein of the present invention.
- Figure 1 shows the flow of BODIPY FL-X-AF-pdCpA ((BFLXAF-pdCpA) separated by HPLC. It is a low chart.
- FIG. 2 is a schematic diagram of BODIPY FL-X-AF-tRNA synthesis. .
- Figure 3 shows BODIPY FL-X-AF, BODIPY FL_AF, BODIPY FL-XK, and BODIPY FL-K introduced into streptavidin using the 4-base method, and fluorescence detection of the resulting streptavidin (right) These are the results of the estamplot analysis (left).
- Figure 4 shows the results of quantifying lysozyme by measuring the fluorescence of an anti-lysozyme antibody (camel antibody) into which BODIPY FL-X-AF was introduced.
- camel antibody anti-lysozyme antibody
- FIG. 5A shows the structural formulas of BODIPY FL-AF, BODIPY R6G-AF, BODIPY 558 / 568-AF and BODIPY 576 / 589-AF. These are each introduced into streptavidin by the 4-base method, and the results of fluorescence detection (B) and Western blot analysis (C) of the resulting streptavidin are shown.
- FIG. 6A shows the structural formulas of Biotin-Lys, Biotin-X-Lys, Biotin-AF, and Biotin-X-AF. Each of these was introduced into the green fluorescent protein by the 4-base method, and the resulting green fluorescent protein was detected by fluorescence detection (B) and subjected to streptavidin-binding Western blot analysis using al force phosphatase (0).
- the supernatant was removed, and the precipitate was again dissolved by adding 20 L of acetonitrile, 1.4 mL of getyl ether was added, and the mixture was stirred and centrifuged at 15,000 rpm for 5 minutes. The supernatant was removed and dried under reduced pressure.
- a DMF solution of pdCpA tetra-n-butylammonium (0.044 ⁇ mol / L) was mixed with 1.1 mol of Boc- ⁇ -Nps-lysine cyanomethylester and allowed to react at room temperature for 2 hours. After confirming the progress of the reaction by reverse phase HPLC (eluent: linear gradient of 0.1% trifluoroacetic acid and methanol), 1.4 mL of getyl ether was added to the reaction solution. The mixture was stirred, centrifuged at 15,000 rpm for 5 minutes, and the supernatant was removed.
- the BocLys-pdCpA of 3 mM DMSO solution 5 ⁇ L, BODIPYFL- SE or BODIPYFL-X-SE to 0.1 M DMSO solution 1 Les DMSO 5 Les 0.1 M NaHCO 3 in (Molecular Probes, Inc.) lO ⁇ L was added, on ice For 30 minutes. After neutralization by adding 1.5 ⁇ L of 1 M acetic acid, the mixture was diluted with 0.1% TFA, and the fraction containing the target compound was recovered by reverse phase HPLC (eluent: linear gradient of 0.1% trifluoroacetic acid and methanol). The solvent was removed by a centrifugal concentrator and dissolved in 50% dioxane.
- I was eccentric.
- the upper layer was collected, an equal amount of black-mouthed form was added, and the mixture was stirred and centrifuged.
- the upper layer was collected, 300 L of ethanol was added, mixed gently, and left at -20 ° C for 1 hour. After centrifugation at 15000 rpm for 30 min at 4 ° C, the supernatant was removed, 200 ⁇ of 70% EtOH stored at -20 ° C was added, and the mixture was centrifuged at 15000 rpm for 4 seconds at 4 ° C. Except for the above, it was dried under reduced pressure.
- ImM was dissolved in potassium acetate ⁇ 4.52 / L.
- FIG. 2 The schematic diagram of the above synthesis reaction is shown in FIG. 2 taking the synthesis of BODIPY FL-X-AF-tRNA as an example. Introduction of BODIPY FL-labeled aminophenylalanine or lysine into the Tyr83 site of streptavidin
- Reaction solution (55 ⁇ m in Hepes-KOH (pH 7.5), 210 mM potassium glutamate, 6.9 mM ammonium acetate, 1.7 mM dithiothreitol, 1.2 mM ATP, 0.28 mM GTP, 26 mM phosphoenolpyruvate, 1 mM Spermidine, 1.9% PO Polyethylene glycol-8000, 35 zg / mL folic acid, 12 mM magnesium acetate, 0.1 raM 20 kinds of amino acids, streptavidin mRNA with T7 Tag added to N-terminus and HisTag added to C-terminus.
- the translation reaction was performed at 37 ° C for 1 hour. Water and 10 L of 2X sample buffer were added to l ⁇ L of the translation reaction solution and heated at 95 ° C for 5 minutes. 5 ⁇ l of the mixture was applied to 15% SDS-PAGE, and after completion, the cells were observed with a Doko Scanner (Moldecular Dynamics FluorImager595, excitation light 488 nm, fluorescence filter 530DF30).
- BODIPY FL-K (BFLK) and BODIPY FL-X-K (BFLXK) were also confirmed to be introduced into streptavidin in the same manner as B, SOD, BODIPY FL-K and BODIPY FL-X-K.
- B, SOD, BODIPY FL-K and BODIPY FL-X-K were also confirmed to be introduced into streptavidin in the same manner as B, SOD, BODIPY FL-K and BODIPY FL-X-K.
- Figure 3 shows the results of Western plot and fluorescence detection. Fluorescence polarization measurement
- MRNA encoding an anti-lysozyme antibody (derived from ratada) with BODIPY FL-X-AF introduced at the N-terminus of the anti-lysozyme antibody, and with a T7 Tag at the N-terminus and a HisTag at the C-terminus (SEQ ID NO: 1)
- BODIPY FL-X-AF-tRNA a translation reaction was performed in the presence of BODIPY FL-X-AF-tRNA in the same manner as for streptavidin.
- 2 mM oxidized glutathione was added instead of dithiothreitol to form disulfide bonds.
- the solvent was removed by a centrifugal concentrator, and trifluoroacetic acid 100 / zL was added and dissolved under ice cooling, and the mixture was left under ice cooling for 5 minutes. After removing trifluoroacetic acid under reduced pressure, add 200 / _iL of water, take a portion, and hydrolyze with 0.1 M NaOH. The amount of released pdCpA was quantified by reversed-phase HPLC, and the concentration of the recovered target compound was determined. After concentration by centrifugation, it was dissolved in DMS0 to a concentration of 2.2 mM.
- the translation reaction, SDS-PAGE, and Western plot were performed in the same manner as for the introduction of BODIPY FL-labeled aminophenylalanine or lysine. However, fluorescence was detected using excitation light of 514 nm and a fluorescence filter of 590DF30.
- the translation reaction and SDS-PAGE were performed in the same manner as for streptavidin using aminoacyl-tRNA to which labeled aminophosphorylalanine or lysine was bound.
- a sample buffer containing no mercaptoethanol was used, and the heat treatment was performed at 50 ° C for 5 minutes.
- the labeled amino acid provided by the present invention is efficiently used in a protein synthesis system, and by using this, a protein having a function derived from a labeled compound can be efficiently synthesized in the protein synthesis system. Therefore, the present invention provides an effective new means for efficiently synthesizing a functional protein.
- SEQ ID NO: 1 shows the sequence of an artificial mRNA of streptavidin fused with a T7 tag and His-Tag labeled with BODIPY-FL.
- sequence of 64 to 96 encodes the T7 tag
- sequence of 112 to 589 encodes streptavidin
- sequence of 590 to 607 encodes His-Tag.
- 358-361 CGGG sequences encode BODIPY FL-X-AF.
- SEQ ID NO: 2 shows the sequence of an artificial mRNA of a camel anti-lysozyme antibody fused to a T7 tag labeled with BODIPY-FL and His-Tag.
- the sequence of 64 to 96 encodes the T7 tag
- the sequence of 116 to 514 encodes the camel anti-lysozyme antibody
- the sequence of 515 to 532 encodes the His-Tag.
- the sequence of 100-103 CGGG encodes BODIPY FL-X-AF.
- SEQ ID NO: 3 shows the sequence of a green fluorescent protein artificial mRNA fused to a BODIPY-FL-labeled T7 tag and His-Tag.
- the sequence of 64 to 96 encodes the T7 tag
- the sequence of 116 to 826 encodes the green fluorescent protein
- the sequence of 827 to 844 encodes the His-tag.
- Code. The sequence of 100-103 CGGG encodes a biotin-labeled amino acid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003281613A AU2003281613A1 (en) | 2002-07-18 | 2003-07-15 | NON-NATURAL LABELED AMINO ACID AND METHOD OF CONSTRUCTING AMINO ACID/tRNA COMPLEX |
EP03741401A EP1439210B1 (en) | 2002-07-18 | 2003-07-15 | aminoacyl-tRNA bound to labelled p-aminophenylalanine or tyrosine |
JP2004522731A JP4362106B2 (ja) | 2002-07-18 | 2003-07-15 | 標識化アミノアシルtRNA |
CA002461654A CA2461654A1 (en) | 2002-07-18 | 2003-07-15 | Non-natural labeled amino acid and method for producing a conjugate of said amino acid and trna |
DE60316103T DE60316103T2 (de) | 2002-07-18 | 2003-07-15 | aminoacyl-tRNA geunden an markierte p-aminophenylalanine oder tyrosine |
US10/490,508 US7385038B2 (en) | 2002-07-18 | 2003-07-15 | Non-natural labeled amino acid and method of constructing amino acid/tRNA complex |
US12/107,435 US20080220477A1 (en) | 2002-07-18 | 2008-04-22 | Non-natural labeled amino acid and method for producing a conjugate of said amino acid and trna |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002209736 | 2002-07-18 | ||
JP2002-209736 | 2002-07-18 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/107,435 Continuation US20080220477A1 (en) | 2002-07-18 | 2008-04-22 | Non-natural labeled amino acid and method for producing a conjugate of said amino acid and trna |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004009709A1 true WO2004009709A1 (ja) | 2004-01-29 |
Family
ID=30767694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/008970 WO2004009709A1 (ja) | 2002-07-18 | 2003-07-15 | 非天然型標識化アミノ酸および該アミノ酸-tRNA結合体の作製方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US7385038B2 (ja) |
EP (1) | EP1439210B1 (ja) |
JP (1) | JP4362106B2 (ja) |
AT (1) | ATE372359T1 (ja) |
AU (1) | AU2003281613A1 (ja) |
CA (1) | CA2461654A1 (ja) |
DE (1) | DE60316103T2 (ja) |
WO (1) | WO2004009709A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005075639A1 (ja) * | 2004-02-06 | 2005-08-18 | Shionogi Co., Ltd. | 拡張コドンを利用した糖タンパク質の作製方法 |
WO2007018315A1 (ja) * | 2005-08-09 | 2007-02-15 | Japan Science And Technology Agency | タンパク質と他の分子との相互作用を検出するためのタンパク質プローブ |
JP2007097423A (ja) * | 2005-09-30 | 2007-04-19 | Protein Express:Kk | 新規な非天然アミノ酸のタンパク質への導入法 |
WO2007046472A1 (ja) * | 2005-10-19 | 2007-04-26 | Olympus Corporation | タンパク質の重合度を測定する方法 |
JP2008503217A (ja) * | 2004-06-18 | 2008-02-07 | アンブレツクス・インコーポレイテツド | 新規抗原結合ポリペプチド及びそれらの使用 |
WO2011105610A1 (ja) * | 2010-02-26 | 2011-09-01 | 国立大学法人名古屋大学 | インスレーター及びその利用 |
JP2012526822A (ja) * | 2009-05-11 | 2012-11-01 | セレクター,インコーポレイティド | 蛍光リン脂質エーテル化合物、組成物、及びその使用 |
US8871181B2 (en) | 2009-05-11 | 2014-10-28 | Cellectar, Inc. | Fluorescent phospholipid ether compounds, compositions, and methods of use |
WO2023048291A1 (ja) | 2021-09-24 | 2023-03-30 | 富士フイルム株式会社 | tRNA、アミノアシルtRNA、ポリペプチド合成用試薬、非天然アミノ酸の導入方法、ポリペプチドの作製方法、核酸ディスプレイライブラリの作製方法、核酸-ポリペプチド連結体及びスクリーニング方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006087821A1 (ja) * | 2005-02-21 | 2006-08-24 | Olympus Corporation | タンパク質とサンプルとの反応を検出する方法 |
KR100925345B1 (ko) * | 2008-01-10 | 2009-11-09 | 주식회사 인트론바이오테크놀로지 | 시험관 전사법으로 준비된 tRNA로부터 제조된 표지자를이용한 시험관 번역법으로 생산되는 단백질의 선택적표지방법 |
US20090286968A1 (en) | 2008-04-25 | 2009-11-19 | Auburn University | 2-Quinoxalinol Salen Compounds and Uses Thereof |
CN104650610A (zh) * | 2015-01-28 | 2015-05-27 | 天津理工大学 | 一种不对称近红外bodipy荧光染料及其制备和应用 |
CN106221280B (zh) * | 2016-08-09 | 2017-10-13 | 东莞理工学院 | 一种含bodipy类共轭单元有机染料敏化剂及其制备方法 |
CN108794518B (zh) * | 2018-04-04 | 2020-06-19 | 安徽师范大学 | 一种以bodipy为基本骨架的有机共轭分子材料及其制备方法 |
CN114560819B (zh) * | 2020-11-27 | 2023-09-19 | 中国海洋大学 | 取代三嗪化合物、其制备方法及在氨基酸、肽、蛋白、细胞标记中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10330299A (ja) * | 1997-05-28 | 1998-12-15 | Aisin Seiki Co Ltd | アミノ酸含有物質の蛍光標識物質 |
WO2000013026A1 (en) * | 1998-08-31 | 2000-03-09 | Amersham Pharmacia Biotech, Inc. | Energy transfer dyes |
JP2001139596A (ja) * | 1999-11-11 | 2001-05-22 | Japan Science & Technology Corp | 発蛍光性ポリアミノ酸誘導体 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2382063A1 (en) * | 1999-09-17 | 2001-03-22 | Shiv Kumar | Charge-modified nucleic acid terminators |
-
2003
- 2003-07-15 WO PCT/JP2003/008970 patent/WO2004009709A1/ja active IP Right Grant
- 2003-07-15 US US10/490,508 patent/US7385038B2/en active Active
- 2003-07-15 DE DE60316103T patent/DE60316103T2/de not_active Expired - Lifetime
- 2003-07-15 EP EP03741401A patent/EP1439210B1/en not_active Expired - Lifetime
- 2003-07-15 AT AT03741401T patent/ATE372359T1/de not_active IP Right Cessation
- 2003-07-15 CA CA002461654A patent/CA2461654A1/en not_active Abandoned
- 2003-07-15 AU AU2003281613A patent/AU2003281613A1/en not_active Abandoned
- 2003-07-15 JP JP2004522731A patent/JP4362106B2/ja not_active Expired - Lifetime
-
2008
- 2008-04-22 US US12/107,435 patent/US20080220477A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10330299A (ja) * | 1997-05-28 | 1998-12-15 | Aisin Seiki Co Ltd | アミノ酸含有物質の蛍光標識物質 |
WO2000013026A1 (en) * | 1998-08-31 | 2000-03-09 | Amersham Pharmacia Biotech, Inc. | Energy transfer dyes |
JP2001139596A (ja) * | 1999-11-11 | 2001-05-22 | Japan Science & Technology Corp | 発蛍光性ポリアミノ酸誘導体 |
Non-Patent Citations (3)
Title |
---|
HIRAO I. ET AL.: "An unnatural base pair for incorporating amino acid analogs into proteins", NATURE BIOTECHNOLOGY, vol. 20, February 2002 (2002-02-01), pages 177 - 182, XP001068466 * |
HOHSAKA T. ET AL.: "Efficient incorporationof nonnatural amino acids with large aromatic groups into streptavidin in in vitro protein synthesizing systems", J. AM. CHEM. SOC., vol. 121, no. 1, 1999, pages 34 - 40, XP000953102 * |
HOHSAKA T. ET AL.: "Incorporation of nonnatural amino acids into streptavidin through in vitro frame-shift suppression", J. AM. CHEM. SOC., vol. 118, no. 40, 1996, pages 9778 - 9779, XP002973328 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005075639A1 (ja) * | 2004-02-06 | 2005-08-18 | Shionogi Co., Ltd. | 拡張コドンを利用した糖タンパク質の作製方法 |
JP2008503217A (ja) * | 2004-06-18 | 2008-02-07 | アンブレツクス・インコーポレイテツド | 新規抗原結合ポリペプチド及びそれらの使用 |
US9175083B2 (en) | 2004-06-18 | 2015-11-03 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
JP4918489B2 (ja) * | 2005-08-09 | 2012-04-18 | 独立行政法人科学技術振興機構 | タンパク質と他の分子との相互作用を検出するためのタンパク質プローブ |
WO2007018315A1 (ja) * | 2005-08-09 | 2007-02-15 | Japan Science And Technology Agency | タンパク質と他の分子との相互作用を検出するためのタンパク質プローブ |
JP2007097423A (ja) * | 2005-09-30 | 2007-04-19 | Protein Express:Kk | 新規な非天然アミノ酸のタンパク質への導入法 |
WO2007046472A1 (ja) * | 2005-10-19 | 2007-04-26 | Olympus Corporation | タンパク質の重合度を測定する方法 |
JP2012526822A (ja) * | 2009-05-11 | 2012-11-01 | セレクター,インコーポレイティド | 蛍光リン脂質エーテル化合物、組成物、及びその使用 |
US8871181B2 (en) | 2009-05-11 | 2014-10-28 | Cellectar, Inc. | Fluorescent phospholipid ether compounds, compositions, and methods of use |
JP2015007118A (ja) * | 2009-05-11 | 2015-01-15 | セレクター,インコーポレイティド | 蛍光リン脂質エーテル化合物、組成物、及びその使用 |
JP2015166372A (ja) * | 2009-05-11 | 2015-09-24 | セレクター,インコーポレイティド | 蛍光リン脂質エーテル化合物、組成物、及びその使用 |
JP2016193907A (ja) * | 2009-05-11 | 2016-11-17 | セレクター,インコーポレイティド | 蛍光リン脂質エーテル化合物、組成物、及びその使用 |
US9616140B2 (en) | 2009-05-11 | 2017-04-11 | Cellectar Biosciences, Inc. | Fluorescent phospholipid ether compounds, compositions, and methods of use |
WO2011105610A1 (ja) * | 2010-02-26 | 2011-09-01 | 国立大学法人名古屋大学 | インスレーター及びその利用 |
WO2023048291A1 (ja) | 2021-09-24 | 2023-03-30 | 富士フイルム株式会社 | tRNA、アミノアシルtRNA、ポリペプチド合成用試薬、非天然アミノ酸の導入方法、ポリペプチドの作製方法、核酸ディスプレイライブラリの作製方法、核酸-ポリペプチド連結体及びスクリーニング方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1439210A1 (en) | 2004-07-21 |
DE60316103T2 (de) | 2008-05-29 |
EP1439210B1 (en) | 2007-09-05 |
US20080220477A1 (en) | 2008-09-11 |
ATE372359T1 (de) | 2007-09-15 |
US7385038B2 (en) | 2008-06-10 |
JPWO2004009709A1 (ja) | 2005-11-17 |
US20070117181A1 (en) | 2007-05-24 |
JP4362106B2 (ja) | 2009-11-11 |
DE60316103D1 (de) | 2007-10-18 |
EP1439210A4 (en) | 2004-11-03 |
CA2461654A1 (en) | 2004-01-29 |
AU2003281613A1 (en) | 2004-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080220477A1 (en) | Non-natural labeled amino acid and method for producing a conjugate of said amino acid and trna | |
Katritzky et al. | Fluorescent amino acids: advances in protein-extrinsic fluorophores | |
US9127164B2 (en) | Fluorescent dyes and uses thereof | |
US7595198B2 (en) | Photocleavable isotope-coded affinity tags | |
US7897787B2 (en) | Maleimide derivative | |
US20060141530A1 (en) | Reagents and procedures for multi-label high-specificity labeling | |
WO2015107071A1 (en) | Genetically encoded spin label | |
JP4917044B2 (ja) | 非天然アミノ酸をタンパク質に導入するためのtRNA変異体 | |
JP4918489B2 (ja) | タンパク質と他の分子との相互作用を検出するためのタンパク質プローブ | |
US7141655B2 (en) | Reagents and procedures for high-specificity labeling | |
Gupta et al. | Facile synthesis of a novel genetically encodable fluorescent α-amino acid emitting greenish blue light | |
WO2003091689A2 (en) | Bis-transition-metal-chelate-probes | |
JP2005534738A (ja) | アクリドン及びキナクリドンの寿命色素を用いるタンパク質の部位特異的標識 | |
US20070161807A1 (en) | Method for manufacturing optically pure coumaryl amino acids and the novel coumaryl aminoacids thus obtained | |
US20050239144A1 (en) | Site-specific labelling of proteins using cyanine dye reporters | |
JP2005534739A (ja) | シアニン染料リポーターを用いたタンパク質の部位特異的標識 | |
JP2005287327A (ja) | 新規な部位特異的蛍光ラベル化タンパク質の合成方法 | |
KR20240055161A (ko) | 화학선택적 전기촉매성 생체접합 반응 및 이의 용도 | |
Durkin et al. | Design and Application of Autofluorescent Proteins by Biological Incorporation of Intrinsically Fluorescent Noncanonical Amino Acids | |
Duckworth | Site-selective modification of proteins using protein farnesyltransferase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004522731 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003281613 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007117181 Country of ref document: US Ref document number: 10490508 Country of ref document: US Ref document number: 2461654 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003741401 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2003741401 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10490508 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003741401 Country of ref document: EP |